Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- AbbVie
- Study ID
- NCT04492020
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ubrogepant 100 mg — DRUGFor each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
- Placebo — DRUGFor each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Study Details
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Key Dates
- First listed
- Jul 30, 2020
- Start date
- Aug 21, 2020
- Status verified
- May 2023
- Primary completion
- Apr 19, 2022
- Completion
- Apr 19, 2022
Study Design
- Enrollment
- 518 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Sequence AParticipants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event
- Experimental: Treatment Sequence BParticipants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event
Primary Outcome Measure
Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose [ Time Frame: 24 hours after taking double-blind study intervention during the prodrome ]
Locations (73)
Find similar trials in Birmingham, AL
Nationwide
By condition
By specialty
Related Studies
- Pain Biomarker StudyPHASE1 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
- Objectively Diagnose and Monitor Treatment of Light SensitivityRecruiting · Randy Kardon · Iowa City, Iowa
- Mind Body Balance for Pediatric MigraineRecruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio
- Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial PainPHASE2 · Recruiting · Stanford University · Stanford, California